Expression and Function of SOCS Proteins in Glial Cells

SOCS 蛋白在胶质细胞中的表达和功能

基本信息

  • 批准号:
    7313365
  • 负责人:
  • 金额:
    $ 25.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-12-15 至 2011-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our goal is to understand the basis of immune and inflammatory responses within the CNS. Immunological activation of macrophages/microglia and astrocytes leads to the production of cytokines that impact on glial and neuronal function. Cytokines have far-reaching effects in the CNS, including the initiation and regulation of immune/inflammatory responses. Macrophages/microglia and astrocytes not only produce cytokines, but also respond to them via cell surface receptors. Macrophage/microglial and astrocytic activation in general is aimed at promoting a beneficial restoration of endangered CNS elements and functions. However, excessive and sustained stimulation of these cells contributes to acute and chronic neuropathologies. Therefore, dysregulation of macrophage/microglial and astrocytic cytokine production and responsiveness may promote direct neurotoxicity, as well as disturb neural cell functions. The biological effects of cytokines are mediated by intracellular signal transduction pathways; the most common being the Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway (JAK-STAT). Cytokines implicated in CNS pathology include IFN-y, IFN-p and IL-6 family members, all of which signal through the JAK-STAT pathway. A precise regulation of both the magnitude and duration of JAK and STAT activation is essential, as dysregulation of the JAK-STAT pathway has pathological implications. Suppressors of Cytokine Signaling (SOCS) proteins function to inhibit the JAK-STAT pathway. SOCS proteins are inducible by cytokines, and inhibit signaling by directly binding to cytokine receptor chains or associated JAKs to inhibit tyrosine kinase activity, thereby functioning in a negative feedback loop. There is limited information regarding the expression and function of SOCS proteins within the CNS. Our preliminary results indicate that both SOCS-1 and SOCS-3 function to attenuate expression of genes critical for immune/inflammatory responses in macrophages/microglia and astrocytes. We hypothesize that expression of SOCS-1/SOCS-3 will attenuate cytokine-induced inflammatory and immune responses by inhibiting activation of these cells, thereby exerting beneficial effects for immune-mediated CNS diseases. We will examine the ability of astrocytes, microglia and macrophages to express SOCS-1/SOCS-3 proteins in response to CNS-relevant stimuli, and elucidate the transcriptional programs underlying SOCS-1/SOCS-3 gene transcription (Aims 1 and 3). The ability of SOCS-1/SOCS-3 to modulate immunological and inflammatory responses in glial cells and macrophages will also be examined (Aims 2 and 4), using macrophage and astroglial cell lines that express siRNA against SOCS-1/SOCS-3 in an inducible manner. Our proposed studies will provide the first biological assessment of SOCS-1/SOCS-3 production and function in cells of the CNS, thereby providing the basis for future assessment of SOCS-1/SOCS-3 as attenuators of inflammatory and neurotoxic responses in the CNS.
描述(由申请人提供):我们的目标是了解中枢神经系统内免疫和炎症反应的基础。巨噬细胞/小胶质细胞和星形胶质细胞的免疫活化导致影响胶质细胞和神经元功能的细胞因子的产生。细胞因子在CNS中具有深远的影响,包括免疫/炎症反应的启动和调节。大胶质细胞/小胶质细胞和星形胶质细胞不仅产生 细胞因子,但也通过细胞表面受体对它们作出反应。巨噬细胞/小神经胶质细胞和星形胶质细胞的激活一般旨在促进濒危CNS元素和功能的有益恢复。然而,这些细胞的过度和持续刺激有助于急性和慢性神经病理学。因此,巨噬细胞/小胶质细胞和星形胶质细胞细胞因子产生和反应性的失调可能会促进直接神经毒性,以及干扰神经细胞功能。细胞因子的生物学效应由细胞内信号转导途径介导;最常见的是Janus激酶(JAK)和信号转导和转录激活因子(STAT)途径(JAK-STAT)。CNS病理学中涉及的细胞因子包括IFN-γ、IFN-β和IL-6家族成员,所有这些都通过JAK-STAT途径发出信号。JAK和STAT激活的幅度和持续时间的精确调节是必不可少的,因为JAK-STAT途径的失调具有病理学意义。细胞因子信号传导抑制因子(SOCS)蛋白的功能是抑制JAK-STAT途径。SOCS蛋白可由细胞因子诱导,并通过直接结合细胞因子受体链或相关JAK抑制酪氨酸激酶活性来抑制信号传导,从而在负反馈环中起作用。 关于SOCS蛋白在肿瘤细胞中的表达和功能的信息有限。 CNS。我们的初步研究结果表明,SOCS-1和SOCS-3的功能,以减弱在巨噬细胞/小胶质细胞和星形胶质细胞的免疫/炎症反应的关键基因的表达。我们假设SOCS-1/SOCS-3的表达将通过抑制这些细胞的活化来减弱马槟榔诱导的炎症和免疫应答,从而对免疫介导的CNS疾病发挥有益作用。我们将研究星形胶质细胞,小胶质细胞和巨噬细胞表达SOCS-1/SOCS-3蛋白的能力,以响应CNS相关刺激,并阐明SOCS-1/SOCS-3基因转录的转录程序(目标1和3)。还将使用以可诱导方式表达针对SOCS-1/SOCS-3的siRNA的巨噬细胞和星形胶质细胞系来检查SOCS-1/SOCS-3调节神经胶质细胞和巨噬细胞中的免疫和炎症应答的能力(目的2和4)。我们提出的研究将提供第一个生物学评估的SOCS-1/SOCS-3的生产和功能的中枢神经系统的细胞,从而为未来的评估SOCS-1/SOCS-3的炎症和神经毒性反应的衰减剂在中枢神经系统提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Etty N Benveniste其他文献

Etty N Benveniste的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Etty N Benveniste', 18)}}的其他基金

Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD
项目 2:验证 JAK/STAT 通路作为 PD 的新型治疗策略
  • 批准号:
    9976624
  • 财政年份:
    2018
  • 资助金额:
    $ 25.38万
  • 项目类别:
Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD
项目 2:验证 JAK/STAT 通路作为 PD 的新型治疗策略
  • 批准号:
    10469388
  • 财政年份:
    2018
  • 资助金额:
    $ 25.38万
  • 项目类别:
Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma
靶向胶质瘤中的 JAK/STAT-3 通路信号轴
  • 批准号:
    8434816
  • 财政年份:
    2012
  • 资助金额:
    $ 25.38万
  • 项目类别:
Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma
靶向胶质瘤中的 JAK/STAT-3 通路信号轴
  • 批准号:
    8237478
  • 财政年份:
    2012
  • 资助金额:
    $ 25.38万
  • 项目类别:
Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma
靶向胶质瘤中的 JAK/STAT-3 通路信号轴
  • 批准号:
    8618781
  • 财政年份:
    2012
  • 资助金额:
    $ 25.38万
  • 项目类别:
Training Program in Brain Tumor Biology
脑肿瘤生物学培训计划
  • 批准号:
    7436144
  • 财政年份:
    2007
  • 资助金额:
    $ 25.38万
  • 项目类别:
Therapeutic Intervention of the JAK/STAT Pathway for Neuroinflammation
JAK/STAT 通路对神经炎症的治疗干预
  • 批准号:
    8630636
  • 财政年份:
    2007
  • 资助金额:
    $ 25.38万
  • 项目类别:
Training Program in Brain Tumor Biology
脑肿瘤生物学培训计划
  • 批准号:
    8871806
  • 财政年份:
    2007
  • 资助金额:
    $ 25.38万
  • 项目类别:
Training Program in Brain Tumor Biology
脑肿瘤生物学培训计划
  • 批准号:
    7638542
  • 财政年份:
    2007
  • 资助金额:
    $ 25.38万
  • 项目类别:
Expression and Function of SOCS Proteins in Glial Cells
SOCS 蛋白在胶质细胞中的表达和功能
  • 批准号:
    7769836
  • 财政年份:
    2007
  • 资助金额:
    $ 25.38万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了